DASHENLIN PHARMACEUTICAL GROUP CO., LTD.

Autres langues DaShenLin Pharmaceutical Group Co., Ltd.

Actions

603233

CNE100002RG2

Pharmacies

Cours en clôture Shanghai S.E. 20/08/2026			Varia. 5j.	Varia. 1 janv.
18,19 ^CNY	+1,56 %		+0,28 %	+3,23 %

24/04	Dashenlin Pharma : le bénéfice net progresse de 11% au premier trimestre	MT
24/04	Dashenlin Pharma : le bénéfice bondit de 35% en 2025, le chiffre d'affaires progresse de 4%	MT

Autres langues

24/04	Dashenlin Pharma's Q1 Profit Rises 11%
24/04	Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4%
23/04	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
23/04	Dashenlin pharmaceutical 2025 net profit up 35.0% y/y
23/04	Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million
22/04	DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.
29/10/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
28/08/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
25/04/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
25/04/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
15/10/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
20/09/24	Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.
18/09/24	DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million.
30/08/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
03/07/24	Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.
07/05/24	DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024.
28/04/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
28/04/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
18/03/24	Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares
05/03/24	Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares
23/01/24	DaShenLin Pharmaceutical Group Co., Ltd. cancelled the transaction announced on January 19, 2023
27/11/23	Dashenlin Pharmaceutical to Boost Stake in Local Pharmacy Chain to 66% For 30 Million Yuan
25/11/23	DaShenLin Pharmaceutical Group Co., Ltd. agreed to acquire 15% stake in Chongqing Wanjiayan Pharmacy Chain Co., Ltd from Chongqing Wanjiayan Health Industry Group Co., Ltd. and Bai Run for CNY 30 million.
30/10/23	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
29/08/23	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023